Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Remitly Global Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Remitly Global Inc trades at $23.5 (market cap $5.03B). The key difference: Remitly Global Inc is the larger of the two by market cap, and Remitly Global Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Remitly Global Inc for 53 Days on average.
| DYN | RELY | |
|---|---|---|
Market Cap | $2.81B | $5.03B |
Volume | 2,195,902 | 2,682,448 |
Sector | Health | Technology |
52-Week High | $26.78 | $26.92 |
52-Week Low | $14.60 | $12.20 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $2.13B | $4.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
RELY trades at $23.76, up 0.93% with strong technical momentum and bullish moving averages. The company demonstrates accelerating revenue growth, reaching $1.64B in 2025 with net income turning positive at $68M. Recent earnings beats and a 92% analyst buy rating support the bullish case, while the stock approaches key resistance at $24-25 levels.
Outlook remains positive with 20% revenue growth and expanding profit margins driving valuation. Key risks include competitive pressures in digital payments and potential market volatility. The consensus price target of $30.50 suggests 28% upside potential from current levels, supported by strong institutional interest and positive business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
